Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211.

TitleResponse to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211.
Publication TypeJournal Article
Year of Publication2009
AuthorsSu Z, Gulick RM, Krambrink A, Coakley E, Hughes MD, Han D, Flexner C, Wilkin TJ, Skolnik PR, Greaves WL, Kuritzkes DR, Reeves JD
Corporate AuthorsAIDS Clinical Trials Group A5211 Team
JournalJ Infect Dis
Volume200
Issue11
Pagination1724-8
Date Published2009 Dec 1
ISSN1537-6613
KeywordsAcquired Immunodeficiency Syndrome, Anti-HIV Agents, CCR5 Receptor Antagonists, CD4 Lymphocyte Count, Double-Blind Method, HIV-1, Humans, Piperazines, Pyrimidines, RNA, Viral, Sensitivity and Specificity, Statistics, Nonparametric, Viral Tropism
Abstract

The enhanced-sensitivity Trofile assay (Monogram Biosciences) was used to retest coreceptor use at both study screening and study entry for 118 treatment-experienced subjects in AIDS Clinical Trials Group A5211 who had CCR5-tropic (R5) virus detected by the original Trofile assay at study screening. Among 90 recipients of vicriviroc, a significantly (P< .001) greater mean reduction in HIV-1 RNA was observed in 72 subjects with R5 virus versus 15 subjects reclassified as having dual/mixed-tropic viruses at screening: -1.11 versus -0.09 log(10) copies/mL at day 14 and -1.91 versus -0.57 log(10) copies/mL at week 24, respectively. Results suggest that the enhanced-sensitivity assay is a better screening tool for determining patient eligibility for CCR5 antagonist therapy.

DOI10.1086/648090
Alternate JournalJ. Infect. Dis.
PubMed ID19874179
PubMed Central IDPMC2783913
Grant ListAI-68636 / AI / NIAID NIH HHS / United States
AI-69419 / AI / NIAID NIH HHS / United States
AI27659 / AI / NIAID NIH HHS / United States
AI27668 / AI / NIAID NIH HHS / United States
AI68634 / AI / NIAID NIH HHS / United States
K23 AI055038 / AI / NIAID NIH HHS / United States
K23 AI055038-01 / AI / NIAID NIH HHS / United States
K23 AI055038-02 / AI / NIAID NIH HHS / United States
K23 AI055038-03 / AI / NIAID NIH HHS / United States
K23 AI055038-04 / AI / NIAID NIH HHS / United States
K23 AI055038-05 / AI / NIAID NIH HHS / United States
K23 AI55038 / AI / NIAID NIH HHS / United States
K24 AI051966 / AI / NIAID NIH HHS / United States
K24 AI051966-01A1 / AI / NIAID NIH HHS / United States
K24 AI051966-02 / AI / NIAID NIH HHS / United States
K24 AI051966-03 / AI / NIAID NIH HHS / United States
K24 AI051966-04 / AI / NIAID NIH HHS / United States
K24 AI051966-05 / AI / NIAID NIH HHS / United States
K24 AI051966-06A1 / AI / NIAID NIH HHS / United States
K24 AI051966-07 / AI / NIAID NIH HHS / United States
K24 AI51966 / AI / NIAID NIH HHS / United States
P30-AI45008 / AI / NIAID NIH HHS / United States
RR024996 / RR / NCRR NIH HHS / United States
U01-AI32783 / AI / NIAID NIH HHS / United States